Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic ColorectalCancer: The TERRA Study Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectalcancer (mCRC) in a phase II Japanese trial. This regional trial evaluated the efficacy and safety of trifluridine/tipiracil in Asian patients with mCRC with or without exposure to biologic
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectalcancer associated with patient outcomes Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR) are determinants of prognosis in colorectalcancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic (...) predictor of prognosis than National Comprehensive Cancer Network high-risk features and was a superior predictor of prognosis compared with genomic (dMMR, pMMR/BRAFwt /KRASwt , pMMR/BRAFmut /KRASwt , pMMR/BRAFwt /KRASmut ) and transcriptomic (CMS 1-4) subtypes.TIL/MMR classification identified subtypes of stage II/III colorectalcancer associated with different outcomes. Although dMMR status is generally considered a marker of good prognosis, we found this to be dependent on the presence of TILs
Reanalysis of All-Cause Mortality in the U.S. Preventive Services Task Force 2016 Evidence Report on ColorectalCancer Screening. 28828493 2018 01 09 2018 11 13 1539-3704 167 8 2017 10 17 Annals of internal medicine Ann. Intern. Med. Reanalysis of All-Cause Mortality in the U.S. Preventive Services Task Force 2016 Evidence Report on ColorectalCancer Screening. 602-603 10.7326/M17-0859 Swartz Andrew W AW From Yukon-Kuskokwim Delta Regional Hospital, Bethel, Alaska, and University of South (...) Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2017 08 22 United States Ann Intern Med 0372351 0003-4819 AIM IM Advisory Committees Colorectal Neoplasms diagnosis mortality Early Detection of Cancer Humans Mass Screening Meta-Analysis as Topic Randomized Controlled Trials as Topic Risk Sigmoidoscopy 2017 8 23 6 0 2018 1 10 6 0 2017 8 23 6 0 ppublish 28828493 2650649 10.7326/M17-0859 PMC5823607 NIHMS941043 Scand J Gastroenterol. 2002 May;37(5):568-73
Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectalcancer Inflammation promotes the development of malignancy, while a variety of systemic markers of inflammation predict for worse cancer outcomes including recurrence and survival. Here, we evaluate the prognostic impact of cytokine concentrations, full blood count (FBC) differential ratios, cognitive function and fatigue on survival in patients with localised colorectal (...) cancer (CRC).Data are from a prospective longitudinal study comparing cognitive function and fatigue in patients with CRC who did (n=173) and did not (n=116) receive adjuvant/neoadjuvant chemotherapy. Baseline blood results (prior to any chemotherapy) included cytokines and FBC from which neutrophil lymphocyte ratio, lymphocyte monocyte ratio, platelet lymphocyte ratio and platelet monocyte ratio were derived. Fatigue was measured with the Functional Assessment of Cancer Therapy-Fatigue subscale
Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for ColorectalCancer: Randomized Controlled Trial People seek information on the Web for managing their colorectalcancer (CRC) risk but retrieve much personally irrelevant material. Targeting information pertinent to this cohort via a frequently asked question (FAQ) format could improve outcomes.We identified and prioritized colorectalcancer information for men and women aged 35 to 74 years (study 1) and built (...) a website containing FAQs ordered by age and gender. In study 2, we conducted a randomized controlled trial (RCT) to test whether targeted FAQs were more influential on intention to act on CRC risk than the same information accessed via a generic topic list. Secondary analyses compared preference for information delivery, usability, relevance, and likelihood of recommendation of FAQ and LIST websites.Study 1 determined the colorectalcancer information needs of Australians (N=600) by sex and age group
Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectalcancer cells Colorectalcancer (CRC) is the third most leading cause of morbidity and mortality throughout the world. 5-fluorouracil (5-FU), which is often administrated to disrupt carcinogenesis, was found to elevate blood glucose level among CRC patients. Thus, this study was conducted to evaluate the influence of rosiglitazone on antiproliferative effect of 5-FU using cellular model. Two
Cost-effectiveness of ColorectalCancer Screening and Treatment Methods: Mapping of Systematic Reviews. Due to extensive literature on colorectalcancer and their heterogeneous results, this study aimed to summarize the systematic reviews which review the cost-effectiveness studies on different aspects of colorectal cancer.The required data were collected by searching the following key words according to MeSH: "colorectalcancer," "colorectal oncology," "colorectal carcinoma," "colorectal (...) neoplasm," "colorectal tumors," "cost-effectiveness," "systematic review," and "meta-analysis." The following databases were searched: PubMed, Cochrane, Google Scholar, and Scopus. Two reviewers evaluated the articles according to the checklist of "assessment of multiple systematic reviews" (AMSTAR) tool.Finally, eight systematic reviews were included in the study. The Drummond checklist was mostly used for assessing the quality of the articles. The main perspective was related to the payer
Lonsurf for Metastatic ColorectalCancer – Details Lonsurf for Metastatic ColorectalCancer – Details | CADTH.ca Find the information you need Lonsurf for Metastatic ColorectalCancer – Details Lonsurf for Metastatic ColorectalCancer – Details Project Number pCODR 10122 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic ColorectalCancer Funding Request For the treatment of adult patients with metastatic (...) colorectalcancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada, Inc. Submitter Taiho Pharma Canada, Inc. Submission Date November 6, 2017 Submission Deemed Complete November 13, 2017 Submission Type New Drug
Microsatellite instability in colorectalcancerColorectalcancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers if it is detected in the early stages. Molecular changes that occur in colorectalcancer may be categorized into three main groups: 1) Chromosomal Instability (CIN), 2) Microsatellite Instability (MSI), and 3) CpG Island (...) as the presence of alternate sized repetitive DNA sequences which are not present in the corresponding germ line DNA. The presence of MSI is found in sporadic colon, gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectalcancers display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications. As well, detecting MSI is used diagnostically for tumor detection and classification. For these reasons, microsatellite instability analysis
Erbitux for Left Sided Metastatic ColorectalCancer – Details Erbitux for Left Sided Metastatic ColorectalCancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic ColorectalCancer – Details Erbitux for Left Sided Metastatic ColorectalCancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic ColorectalCancer Funding Request For the first-line treatment
Vectibix for Left Sided Metastatic ColorectalCancer — Details Vectibix for Left Sided Metastatic ColorectalCancer – Details | CADTH.ca Find the information you need Vectibix for Left Sided Metastatic ColorectalCancer – Details Vectibix for Left Sided Metastatic ColorectalCancer – Details Project Number pCODR 10118 Brand Name Vectibix Generic Name Panitumumab Strength 20 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic ColorectalCancer Funding Request In combination
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectalcancer: learning from a clinical case Constitutive activation of HER2-dependent intracellular signalling by HER2 gene amplification or by HER2 mutations has been demonstrated as a mechanism of primary and secondary cancer resistance to cetuximab or panitumumab in preclinical and clinical models of metastatic colorectalcancer (mCRC). Both HER2 Amplification for Colorectal (...) Cancer Enhanced Stratification (HERACLES) cohort A and My Pathway clinical trials provided clinical evidence that anti-HER2 therapies could be active in these patients.HER2 gene amplification and HER2 protein overexpression analysis were performed in tumour tissue by fluorescence in situ hybridisation and immunohistochemistry. HER2 positivity was defined according to HERACLES CRC-specific HER2 scoring criteria. DNA analysis for multiple assessment of gene mutations or amplifications was carried out
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectalcancer: a randomized phase II trial-PRODIGE 20 study results. 29718089 2018 12 20 1569-8041 29 11 2018 Nov 01 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectalcancer: a randomized phase II trial-PRODIGE 20 study results. 2270 10.1093
ColorectalcancerColorectalcancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Colorectalcancer Last reviewed: February 2019 Last updated: January 2018 Summary Third most common cancer in the Western world. Rare below 40 years of age. Symptoms are not specific and occur frequently in benign colorectal conditions. Surgical resection is the main curative treatment. Combined modality treatment (chemotherapy (...) , radiotherapy, resection of metastases) has increased survival in selected cases. Definition The majority of colorectalcancers are adenocarcinomas derived from epithelial cells. About 71% of new colorectalcancers arise in the colon and 29% in the rectum. Toms JR, ed. CancerStats monograph 2004. London: Cancer Research; 2004. Less common types of malignant colorectal tumours are carcinoid tumours, GI stromal cell tumours, and lymphomas. Increasing age is the greatest risk factor for sporadic colorectal
Revised Australian national guidelines for colorectalcancer screening: family history Revised Australian national guidelines for colorectalcancer screening: family history | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Revised Australian national guidelines for colorectalcancer screening: family history Mark A Jenkins, Driss Ait Ouakrim, Alex Boussioutas, John L Hopper, Hooi C Ee, Jon D Emery, Finlay A Macrae, Albert Chetcuti, Laura Wuellner and D James B St John Med J Aust 2018; 209 (10): . || doi: 10.5694/mja18.00142 Published online: 29 October 2018 Topics Abstract Introduction: Screening is an effective means for colorectalcancer prevention
High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectalcancer consortia. Colorectalcancer (CRC) remains the third most common cancer worldwide, with a growing incidence among young adults. Multiple studies have presented associations between the gut microbiome and CRC, suggesting a link with cancer risk. Although CRC microbiome studies continue to profile larger patient cohorts with increasingly economical and rapid DNA sequencing platforms (...) , few common associations with CRC have been identified, in part due to limitations in taxonomic resolution and differences in analysis methodologies. Complementing these taxonomic studies is the newly recognized phenomenon that bacterial organization into biofilm structures in the mucus layer of the gut is a consistent feature of right-sided (proximal), but not left-sided (distal) colorectalcancer. In the present study, we performed 16S rRNA gene amplicon sequencing and biofilm quantification